Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials

Lung cancer is the leading cause of cancer-related death across the world. Unlike lung adenocarcinoma, patients with lung squamous cell carcinoma (LSCC) have not benefitted from targeted therapies. Although immunotherapy has significantly improved cancer patients’ outcomes, the relatively low respon...

Descripción completa

Detalles Bibliográficos
Autores principales: Niu, Zhenyi, Jin, Runsen, Zhang, Yan, Li, Hecheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535022/
https://www.ncbi.nlm.nih.gov/pubmed/36198685
http://dx.doi.org/10.1038/s41392-022-01200-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535022/
https://www.ncbi.nlm.nih.gov/pubmed/36198685
http://dx.doi.org/10.1038/s41392-022-01200-x

Ejemplares similares